Navigation Links
Cancer immunotherapy shows long-term promise in lung cancer
Date:4/24/2008

New, long-term results from a clinical trial presented today at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) and the International Association of the Study of Lung Cancer (IASLC) show that MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic), an immune-boosting treatment for lung cancer patients, reduces the risk of relapse after surgery -- to the same extent as chemotherapy but without the side-effects of chemotherapy.

Prof. Johan Vansteenkiste from University Hospital Gasthuisberg in Belgium described the results after 44-months follow-up from a double-blind, placebo-controlled trial in 182 patients with non-small-cell lung cancer -- the most common form of the disease.

After complete surgical resection of the tumor, patients were randomly assigned to receive either placebo injections or injections of MAGE-A3 ASCI administered over 27 months (five given at three-week intervals followed by eight given once every three months). MAGE-A3 is a tumor-specific antigen, expressed in 35-50% of non-small-cell lung cancer, but not on normal cells.

"The aim is to help the body immune system to recognize the MAGE-A3 antigen and therefore eliminate the cancer cells that express MAGE-A3," explains Prof. Vansteenkiste. "In other words, it is a kind of treatment method that makes the body immune system specifically attack the lung cancer cells."

After 44 months, 69 of 182 patients had experienced a recurrence of their cancer, including 57 deaths. Those given the MAGE-A3 injections had longer on average before their cancer recurred, were less likely to have any recurrence, and were less likely to die.

"Surgical resection is the standard treatment for patients with early stage lung cancer, but after complete resection about 50% will relapse and die from their cancer," says Prof. Vansteenkiste. "Postoperative chemotherapy is able to improve cure rates, but is sometimes poorly tolerated by patients recovering from thoracic surgery. In addition, not all patients are fit to receive chemotherapy. This is why the signal from this phase II randomized study is important: the reduction in risk of postoperative cancer relapse is similar to the one obtained with postoperative chemotherapy, while the side-effects of this new strategy are minimal compared to chemotherapy."

Most patients only experience mild reactions at the injection site and fever within 24 hours of the injection, he explained. "Therefore, it is suitable for long-term maintenance treatment and for most patients, including older patients or patients in weak physical condition after surgery, allowing them to live a normal life whilst on cancer treatment." A large Phase III trial of the therapy, named MAGRIT, is now underway.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
41-919-731-907
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. Researchers reveal structure of protein that repairs damage to cancer cells
2. Pregnancy is possible after cancer treatment
3. Effective cancer immune therapy through order in the blood vessels
4. Fox Chase researchers discover a method for clamping down on a cancer-promoting enzyme
5. Breast cancers behave differently before and after the age of 70
6. Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
7. Ovarian cancer stem cells identified, characterized
8. Inherited cancer mutation is widespread in America
9. New type of drug shrinks primary breast cancer tumors significantly in just 6 weeks
10. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
11. Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):
(Date:5/4/2016)... ... May 04, 2016 , ... Proove Biosciences, Inc. , ... strategic partnership with McGill University . The partnership is designed to advance research ... order to help patients in pain. With the new agreement, researchers at Proove Biosciences ...
(Date:5/4/2016)... ... May 04, 2016 , ... PBI-Gordon Corporation is pleased ... Sales. , Doug began his career at PBI-Gordon in February 1988, after finishing ... wide variety of roles, ranging from customer service to national product manager, to helping ...
(Date:5/3/2016)... ... , ... In a list published by the Boston Business Journal, iLab ... a small percentage of the state's 615,000+ small businesses. The list examined companies based ... from 2012 to 2015. , As this award comes on the heels ...
(Date:5/3/2016)... ... May 03, 2016 , ... Wearable ... and data driven conferences, will take place on June 7-8, 2016, at the New York ... Raman-Tangella on incorporating technology -- including AR/VR, machine learning, apps, robotics and AI -- ...
Breaking Biology Technology: